CA2236989A1 - Therapie innovatrice pour le traitement du deficit du stockage lysosomal - Google Patents
Therapie innovatrice pour le traitement du deficit du stockage lysosomal Download PDFInfo
- Publication number
- CA2236989A1 CA2236989A1 CA002236989A CA2236989A CA2236989A1 CA 2236989 A1 CA2236989 A1 CA 2236989A1 CA 002236989 A CA002236989 A CA 002236989A CA 2236989 A CA2236989 A CA 2236989A CA 2236989 A1 CA2236989 A1 CA 2236989A1
- Authority
- CA
- Canada
- Prior art keywords
- disease
- mps
- microcapsules
- lysosomal storage
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002236989A CA2236989A1 (fr) | 1998-05-06 | 1998-05-06 | Therapie innovatrice pour le traitement du deficit du stockage lysosomal |
AU35141/99A AU3514199A (en) | 1998-05-06 | 1999-05-06 | Novel therapy for treatment of lysosomal storage disease |
PCT/CA1999/000368 WO1999056770A2 (fr) | 1998-05-06 | 1999-05-06 | Nouveau traitement des maladies a de lysosomes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002236989A CA2236989A1 (fr) | 1998-05-06 | 1998-05-06 | Therapie innovatrice pour le traitement du deficit du stockage lysosomal |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2236989A1 true CA2236989A1 (fr) | 1999-11-06 |
Family
ID=4162400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002236989A Abandoned CA2236989A1 (fr) | 1998-05-06 | 1998-05-06 | Therapie innovatrice pour le traitement du deficit du stockage lysosomal |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU3514199A (fr) |
CA (1) | CA2236989A1 (fr) |
WO (1) | WO1999056770A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7122177B2 (en) | 2000-01-20 | 2006-10-17 | Diabcell Pty Ltd. | Preparation and xenotransplantation of porcine islets |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5543390A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
-
1998
- 1998-05-06 CA CA002236989A patent/CA2236989A1/fr not_active Abandoned
-
1999
- 1999-05-06 WO PCT/CA1999/000368 patent/WO1999056770A2/fr active Application Filing
- 1999-05-06 AU AU35141/99A patent/AU3514199A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1999056770A2 (fr) | 1999-11-11 |
WO1999056770A3 (fr) | 2000-01-13 |
AU3514199A (en) | 1999-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ross et al. | Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells | |
Haskins | Gene therapy for lysosomal storage diseases (LSDs) in large animal models | |
Chang et al. | The in vivo delivery of heterologous proteins by microencapsulated recombinant cells | |
Floyd et al. | Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles | |
EP2269658B1 (fr) | Therapie genique pour troubles neurometaboliques | |
ES2635726T3 (es) | Terapia génica para enfermedades de almacenamiento lisosómico | |
CA2947468C (fr) | Vecteurs derives de virus adeno-associes pour le traitement de troubles du stockage lysosomal | |
Marcó et al. | In vivo gene therapy for mucopolysaccharidosis type III (Sanfilippo syndrome): a new treatment horizon | |
EP3101125A1 (fr) | Vecteurs viraux recombinés adéno-associés pour le traitement de la mucopolysaccharidose | |
Novelli et al. | Gene therapy for lysosomal storage disorders | |
Hobert et al. | Neuronal ceroid lipofuscinoses therapeutic strategies: past, present and future | |
US20230332112A1 (en) | Novel In Vitro and In Vivo Enrichment Strategy Targeting Lymphocytes Derived from Vector Transduced HSCS for Therapy of Disorders | |
US20230201373A1 (en) | Crispr-mediated genome editing with vectors | |
Suzuki et al. | Mouse models of human lysosomal diseases | |
Sands et al. | Gene therapy for murine mucopolysaccharidosis type VII | |
US20040082535A1 (en) | Products and methods for gaucher disease therpy | |
Vogler et al. | Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease | |
d’Azzo | Gene transfer strategies for correction of lysosomal storage disorders | |
Tomanin et al. | Non‐viral transfer approaches for the gene therapy of mucopolysaccharidosis type II (Hunter syndrome) | |
Salvetti et al. | Gene theraphy of lysosomal storage disorders | |
CA2236989A1 (fr) | Therapie innovatrice pour le traitement du deficit du stockage lysosomal | |
Lagranha et al. | In vitro correction of ARSA deficiency in human skin fibroblasts from metachromatic leukodystrophy patients after treatment with microencapsulated recombinant cells | |
Chang | Microencapsulation—an alternative approach to gene therapy | |
Poenaru | From gene transfer to gene therapy in lysosomal storage diseases affecting the central nervous system | |
Sly | Enzyme replacement therapy: from concept to clinical practice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |